Eton Pharmaceuticals, Inc (ETON) is adding another planned 2026 launch to its rare-disease portfolio as the company secured exclusive U.S. commercialization rights to IMPAVIDO, the only FDA-approved oral therapy for multiple forms of leishmaniasis.
Eton announced that it has entered a supply and distribution agreement with an affiliate of Knight Therapeutics, giving the company exclusive U.S. rights to IMPAVIDO beginning September 26, 2026.
The drug is approved for visceral, cutaneous, and mucosal leishmaniasis in adults and adolescents aged 12 and older who weigh more than 30 kilograms.
Leishmaniasis is a rare parasitic disease transmitted through infected sand flies and can cause severe skin lesions, mucosal damage, or systemic infection affecting internal organs. The most severe form, visceral leishmaniasis, can be fatal if untreated.
IMPAVIDO has been commercially available in the U.S. since 2016 and remains the only oral therapy approved for these specific Leishmania species.
Eton CEO Sean Brynjelsen called IMPAVIDO a "critical, life-saving medication" and highlighted its strong fit with the company's orphan-focused commercial model, noting plans to ensure reliable, high-touch access for patients nationwide. The company said the agreement further expands its portfolio of specialized rare-disease therapies and supports its strategy of building differentiated commercialization and patient-support capabilities.
Along with IMPAVIDO Eton currently markets ten rare-disease products: KHINDIVI, INCRELEX, ALKINDI SPRINKLE, DESMODA, GALZIN, HEMANGEOL, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, and has four additional candidates in late-stage development: Amglidia, ET-700, ET-800 and the ZENEO hydrocortisone autoinjector.
ETON has traded between $13.09 and $33.41 over the past year. The stock closed Tuesday's trading at $32.89, up 1.23%. During afterhours trading the stock was at $33.91, up 3.10%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.